Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
A randomized controlled trial (RCT) involving 25 patients with psoriasis and T2DM demonstrated that 12 weeks of treatment with liraglutide caused a marked decline in the Psoriasis Area and Severity Index (PASI) score
.webp)
The trial, funded by Novo Nordisk, the manufacturer of Wegovy (semaglutide), found the drug improved liver inflammation, scarring (fibrosis), and sometimes both in people with metabolic dysfunction-associated steatohepatitis (MASH)
results depend mainly on the overall plan
What Makes Semaglutide Different Uses a single hormone pathway (GLP-1) to support appetite control Often a great option for patients who prefer a more gradual approach Well-studied with a long track record in metabolic care What Makes Tirzepatide Different Activates two hormone pathways (GLP-1 and GIP) for broader metabolic support May provide stronger appetite suppression for some patients Often considered for patients who need additional metabolic support or have experienced plateaus What Clinical Trials Show GLP-1s Can Do The Proof in the Data Semaglutide By week 68, 86.4% lost at least 5%, 69.1% lost at least 10%, and 50.5% lost at least 15%
